To explore the molecular mechanisms of splicing-related kinases and seek potential therapeutic opportunities for cancer, we performed compound screening and identified a series of novel compounds that inhibit the kinase activities of CLK and SRPK family members. This evidence concerns the gene CLK1 and cancer.